Efficacy of interferon-alpha 2b treatment in children with chronic hepatitis B who have previously undergone therapy for cancer

Basit Öğe Kaydı
dc.contributor.authorKasirga, E
dc.contributor.authorIsenlik, S
dc.contributor.authorAksoylar, S
dc.contributor.authorYaprak, I
dc.contributor.authorKansoy, S
dc.contributor.authorYuce, G
dc.date.accessioned2019-10-27T18:22:00Z
dc.date.available2019-10-27T18:22:00Z
dc.date.issued2000
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: The aim of the present study was to evaluate the efficacy of treatment with recombinant interferon (IFN)-alpha 2b in 12 children with chronic hepatitis B who had previously undergone therapy for cancer. Methods: Nine children had acute leukemias and the other three children had solid tumors. The mean (+/-SD) age of the children was 8.4 +/- 3.8 years (range 4-16 years). All cases were hepatitis B virus (HBV)-DNA positive and 11 were hepatitis B e antigen (HBeAg) positive. One was anti-HBe positive (mutant strain). Four cases were anti-delta IgG positive. Liver biopsy revealed chronic hepatitis B in 11 patients and cirrhosis in one patient. Interferon-alpha 2b was given at a dose of 5 MU/m(2) three times a week, subcutaneously, for 12 months. Results: Elimination of serum HBV-DNA was obtained in three cases, but a further three patients demonstrated a marked decrease in HBV-DNA levels after therapy. Three of 11 patients seroconverted from HBeAg to anti-HBe. Alanine aminotransferase (ALT) levels returned to normal in three of nine cases in whom the ALT levels were high before treatment. At the end of therapy, the mean histologic activity index score was significantly diminished (P = 0.0039). Conclusions: In conclusion, a 12 month course of IFN-alpha 2b induces some beneficial effects on virologic, biochemical and histologic indices in children with chronic hepatitis B who have previously undergone therapy for cancer.en_US
dc.identifier.doi10.1046/j.1442-200x.2000.01312.xen_US
dc.identifier.endpage646en_US
dc.identifier.issn1328-8067
dc.identifier.issn1442-200X
dc.identifier.issue6en_US
dc.identifier.pmid11192521en_US
dc.identifier.startpage642en_US
dc.identifier.urihttps://doi.org/10.1046/j.1442-200x.2000.01312.x
dc.identifier.urihttps://hdl.handle.net/11454/35954
dc.identifier.volume42en_US
dc.identifier.wosWOS:000166527400009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofPediatrics Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcanceren_US
dc.subjectchronic hepatitis Ben_US
dc.subjectinterferon-alpha 2ben_US
dc.titleEfficacy of interferon-alpha 2b treatment in children with chronic hepatitis B who have previously undergone therapy for canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu